Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) CFO Rebecca Chambers sold 3,561 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $49.73, for a total transaction of $177,088.53. Following the completion of the transaction, the chief financial officer owned 173,280 shares in the company, valued at approximately $8,617,214.40. The trade was a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Veracyte Stock Performance
Veracyte stock opened at $49.94 on Friday. The firm’s 50-day moving average is $37.48 and its 200-day moving average is $39.01. Veracyte, Inc. has a 1 year low of $22.61 and a 1 year high of $50.71. The company has a market cap of $3.98 billion, a P/E ratio of 45.82 and a beta of 1.98.
Veracyte (NASDAQ:VCYT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.18. Veracyte had a net margin of 16.25% and a return on equity of 9.07%. The company had revenue of $139.07 million for the quarter, compared to the consensus estimate of $130.36 million. During the same period last year, the firm posted $0.31 EPS. The company’s revenue for the quarter was up 21.5% on a year-over-year basis. As a group, sell-side analysts predict that Veracyte, Inc. will post 1.28 earnings per share for the current year.
Institutional Investors Weigh In On Veracyte
Key Headlines Impacting Veracyte
Here are the key news stories impacting Veracyte this week:
- Positive Sentiment: Veracyte has remained up sharply since its last earnings report, reflecting continued investor confidence in the company’s recent results and outlook. Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
- Positive Sentiment: The company also highlighted ASCO findings from its OPTIMA and ENZAMET Phase III breast and prostate cancer trials, which could help reinforce Veracyte’s growth narrative in precision diagnostics. Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer – Slideshow
- Neutral Sentiment: Canaccord Genuity reiterated a Hold rating on Veracyte, suggesting analysts remain cautious despite the recent rally. Canaccord Genuity Reaffirms Their Hold Rating on Veracyte (VCYT)
- Neutral Sentiment: Veracyte presented at the William Blair Growth Stock Conference, a routine investor-relations event that may help maintain visibility but is unlikely to move the stock on its own. Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock Conference – Slideshow
- Negative Sentiment: Several executives sold shares on June 4, including CEO Marc Stapley, CFO Rebecca Chambers, EVP Annie McGuire, and insider John Leite. The sales were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, which limits the bearish signal, but the size of the CEO sale could still pressure sentiment. Marc Stapley insider trade
Analyst Upgrades and Downgrades
VCYT has been the subject of several analyst reports. Jefferies Financial Group initiated coverage on shares of Veracyte in a report on Monday, April 13th. They set a “buy” rating and a $45.00 price target for the company. Canaccord Genuity Group boosted their price target on shares of Veracyte from $40.00 to $42.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. Morgan Stanley reduced their price target on shares of Veracyte from $48.00 to $37.00 and set an “underweight” rating for the company in a report on Thursday, March 5th. UBS Group lifted their price target on Veracyte from $48.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Zacks Research downgraded Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Veracyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.
View Our Latest Report on Veracyte
About Veracyte
Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.
The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.
Featured Articles
- Five stocks we like better than Veracyte
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
